{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Big Questions Answered","title":"Tackling the drug affordability challenge","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/82038f4a\"></iframe>","width":"100%","height":180,"duration":722,"description":"Ed DeVaney, President, CVS Caremark, shares how we deliver savings to clients and members by challenging the status quo.\n• After saving customers more than $1.8 billion by replacing Humira with lower-cost, FDA-approved biosimilars, CVS Caremark now prefers biosimilars for more than 10 drugs on its template formularies, Ed says. \n• CVS Caremark is adding Zepbound back to its commercial template formulary on Oct. 1 after using its scale to drive competition and reduce GLP-1 costs.  \n• “Our focus is on lowering costs, providing a best-in-class member experience, being hyper-transparent and consultative,” Ed says.","thumbnail_url":"https://img.transistorcdn.com/a6EDx1Rr1wWLwjx3Sp_sYH7qMcRbBtF57BE_lnwvBS4/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9iYWUw/NTE2YThjNTBmNGQ0/NzhlODE1YTdjNzlk/ZmZlZi5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}